SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 61.60-3.7%9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (7611)12/27/2002 11:27:52 PM
From: John Metcalf  Read Replies (3) of 52153
 
Happy holidays, and many thanks to you.

siliconinvestor.com

This column, reposted, argues against many of the principles we have used. For example, it says that benefit to a sub-group in a clinical trial might take precedence over an FDA-agreed protocol.

This case is presented persuasively; even to me, who tends to discard sub-group analyses. Am I buying the Tiny Tim argument, after three apparitions, or might this guy be correct?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News